相关实验视频
Updated: Sep 16, 2025

08:04
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
Published on: June 10, 2025
422
肝细胞染色体P450酶系统与血小板功能和心血管结果的相互作用 - - 药物基因组对器官间通信的影响
Marta Figueiral1,2, Abdullah Al-Abcha1, Matteo Castrichini1
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Comprehensive Physiology
|July 8, 2025
概括
遗传变异影响抗血小板药物的有效性,影响心血管健康. 基因型导向疗法通过根据个体遗传特征量身定制抗血小板药物选择来优化治疗.
科学领域:
- 心血管医学 心血管医学
- 药物基因组学 药物基因组学
- 血液学 血液学 血液学
背景情况:
- 血小板对于静血和血栓形成至关重要.
- 抗血小板药物的疗效受遗传学和肝脏代谢的影响.
- 个体遗传变异会影响药物反应和心血管结果.
研究的目的:
- 探索遗传学,肝功能和抗血小板治疗之间的相互作用.
- 突出基因变异在调节血小板功能和药物代谢中的作用.
- 强调基因型导向疗法的潜力,以实现个性化的心血管治疗.
主要方法:
- 对有关血小板功能,药物基因组学和抗血小板药物相互作用的当前文献的综述.
- 分析肝脏P450酶和遗传多态化 (例如CYP2C19) 对药物代谢的影响.
- 检查遗传变异如何影响抗血小板药物的疗效和患者的结果.
主要成果:
- 遗传变异,特别是CYP2C19,显著影响克洛皮多格雷尔的新陈代谢和抗血小板反应.
- 肝脏的P450酶在药物代谢中起着关键作用,影响循环中的活性药物水平.
- 个人遗传差异可能会削弱抗血小板治疗的疗效.
结论:
- 基因型引导的抗血小板治疗提供了一个个性化的方法来减少缺血和出血事件.
- 了解药物基因相互作用和肝脏的作用对于优化抗血小板治疗至关重要.
- 根据遗传特征量身定制的抗血小板疗法可以提高治疗结果,并最大限度地减少不良影响.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
652
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
652
Factors Affecting Protein-Drug Binding: Drug Interactions
286
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
286
Factors Affecting Drug Biotransformation: Biological
252
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
252
Hepatic Drug Clearance: Effect of Protein Binding
288
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
288
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
84
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
84
Drug Metabolism: Phase I Reactions
3.7K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.7K

